Middlebrook Pharmaceuticals discovered in 2000 that bacteria exposed to antibiotics in front-loaded, sequential bursts, or pulses, are killed more efficiently than those exposed to standard antibiotic treatment regimens. The company went on to develop novel anti-infective pulsatile drug products that take advantage of this discovery.

Middlebrook is applying their technology to drugs that may have lost their effectiveness in previous applications. The advantages of pulse therapy are: once-a-day formulation, lower dosages, shorter duration of therapy, reduced side effects, reduced incidence of resistance, combination products with superior efficacy over either product alone, and improved pediatric and geriatric dosages.

The $100M investment in Middlebrook should be exciting for investors. However, some Middlebrook investors were hoping for an outright buyout at $6 to $8 dollars a share by a larger pharmaceutical. This investment shows that the company is viable, and that a serious investment company such as Equity Group Investments, LLC would not have moved